Compare CRC & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRC | TFX |
|---|---|---|
| Founded | 2014 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.6B |
| IPO Year | N/A | 1994 |
| Metric | CRC | TFX |
|---|---|---|
| Price | $66.24 | $119.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $70.13 | ★ $138.75 |
| AVG Volume (30 Days) | ★ 1.2M | 645.8K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.36% | 1.18% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,992,713,000.00 |
| Revenue This Year | $10.34 | $15.97 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | $13.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.69 | $100.18 |
| 52 Week High | $71.98 | $138.93 |
| Indicator | CRC | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 60.81 |
| Support Level | $45.54 | $117.09 |
| Resistance Level | $66.35 | $123.74 |
| Average True Range (ATR) | 2.27 | 3.27 |
| MACD | -0.26 | 0.81 |
| Stochastic Oscillator | 39.44 | 89.54 |
California Resources Corp is an independent oil and natural gas exploration and production company operating properties exclusively within California. It provides affordable and reliable energy in a safe and responsible manner, to support and enhance the quality of life of Californians and the local communities in which the company operates. It has some of the lowest carbon intensity production in the United States and is focused on maximizing the value of its land, mineral, and technical resources for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.